Omeros Corporation
$ 10.26
-4.29%
02 Jun - close price
- Market Cap 775,864,000 USD
- Current Price $ 10.26
- High / Low $ 10.65 / 10.21
- Stock P/E 9.40
- Book Value -1.69
- EPS 1.14
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -5.76 %
- 52 Week High 17.65
- 52 Week Low 2.95
About
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Analyst Target Price
$40.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-31 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-13 | 2024-08-07 | 2024-04-01 | 2024-03-26 | 2023-11-09 | 2023-08-09 |
| Reported EPS | 0.9771 | -0.5464 | -0.34 | -0.43 | -0.5408 | -0.55 | -0.64 | -0.97 | -0.63 | -0.15 | -0.6 | -0.59 |
| Estimated EPS | -0.1244 | -0.5202 | -0.45 | -0.46 | -0.58 | -0.71 | -0.7 | -1.14 | -0.58 | -0.55 | -0.62 | -0.57 |
| Surprise | 1.1015 | -0.0262 | 0.11 | 0.03 | 0.0392 | 0.16 | 0.06 | 0.17 | -0.05 | 0.4 | 0.02 | -0.02 |
| Surprise Percentage | 885.4502% | -5.0365% | 24.4444% | 6.5217% | 6.7586% | 22.5352% | 8.5714% | 14.9123% | -8.6207% | 72.7273% | 3.2258% | -3.5088% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OMER
2026-06-02 07:39:55
Omeros Corporation is initiated with a Hold rating due to the balanced risk/reward profile following YARTEMLEA's encouraging commercial launch. While Q1 2026 sales exceeded expectations, long-term adoption and payer confidence remain concerns due to limited clinical data. The valuation appears to price in specific peak sales figures, and upcoming catalysts include J-code, NTAP, EMA decision, and ex-US partnerships.
2026-06-01 15:38:57
Omeros (OMER) announced pivotal fourth-quarter 2025 results, highlighted by the divestiture of zaltenibart rights to Novo Nordisk for up to $2.1 billion and the FDA approval and U.S. launch of YARTEMLEA for TA-TMA. The company reported a net income of $86.5 million and significantly strengthened its balance sheet by repaying substantial debt. Omeros also detailed successful early adoption and reimbursement for YARTEMLEA and provided updates on its diverse clinical pipeline.
2026-05-28 02:39:32
Omeros Corp director Thomas J. Cable sold 7,500 shares of company stock worth $87,039 on May 22, 2026, as part of a Rule 10b5-1 trading plan. This transaction followed his exercise of vested stock options for the same number of shares. The sale occurred after a significant stock gain over the past year, though the stock recently declined and is trading above its fair value according to InvestingPro analysis.
2026-05-27 23:09:09
Omeros Corp director Thomas J. Cable sold 7,500 shares of the company’s common stock for $87,039 on May 22, 2026. This transaction was part of a Rule 10b5-1 trading plan and occurred shortly after he exercised stock options. The sale comes amidst a significant stock gain over the past year, though the stock recently declined and trades above its fair value according to InvestingPro.
2026-05-27 22:09:40
Omeros Corp director, Thomas J. Cable, sold 7,500 shares of the company's common stock for $87,039 on May 22, 2026, as part of a Rule 10b5-1 trading plan. This sale followed an exercise of vested stock options for an equal number of shares. The transaction occurs amidst a significant stock gain over the past year, though the stock has recently declined and trades above its Fair Value according to InvestingPro analysis, coinciding with the company reporting a significant miss on its first-quarter 2026 earnings.
2026-05-27 22:09:09
Omeros (NASDAQ: OMER) director Thomas J. Cable exercised stock options for 7,500 shares at $10.84 per share and subsequently sold all 7,500 shares at a weighted average price of $11.6052 per share under a pre-established Rule 10b5-1 trading plan. After these transactions, Cable directly holds 35,067 shares of Omeros common stock. The sales ranged from $11.46 to $11.93 per share, and the options were set to expire on June 9, 2026.
